Trial Profile
A Randomized, Single-Center, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of TAK-792 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sucunamostat (Primary)
- Indications Diabetes mellitus; Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Takeda
- 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Nov 2015 Protocol has been amended in treatment table in change of TAK-792 dose from 900 mg to 1250 mg.